Clinical trials
Phase 1 Leukemia, B-Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
57 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 7 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Unknown status | 14 |
| Active, not recruiting | 6 |
| Recruiting | 4 |
| Not yet recruiting | 3 |
| Withdrawn | 2 |
| Terminated | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Baylor College of Medicine | 4 |
| Memgen, LLC | 3 |
| Celgene | 2 |
| Lomond Therapeutics Holdings, Inc. | 2 |
| National Cancer Institute (NCI) | 2 |
| Pharmacyclics LLC. | 2 |
| iCell Gene Therapeutics | 2 |
| AbbVie | 1 |
| Affimed GmbH | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, B-Cell | 57 |
| Lymphoma, B-Cell | 21 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 19 |
| Lymphoma, Non-Hodgkin | 14 |
| Leukemia | 12 |
| Recurrence | 12 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 |
| Burkitt Lymphoma | 7 |
| Lymphoma | 7 |
| Waldenstrom Macroglobulinemia | 5 |
Trials
Showing 1 to 25 of 57. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.